SAGE Therapeutics Inc (NASDAQ:SAGE) hit a new 52-week high on Tuesday . The stock traded as high as $188.87 and last traded at $187.97, with a volume of 222894 shares traded. The stock had previously closed at $178.77.

Several equities research analysts have recently weighed in on the company. Canaccord Genuity set a $220.00 target price on SAGE Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 8th. LADENBURG THALM/SH SH set a $220.00 target price on SAGE Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Wedbush set a $190.00 target price on Home Depot and gave the stock a “hold” rating in a research report on Wednesday, May 22nd. Oppenheimer set a $18.00 target price on Vanda Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, May 5th. Finally, Raymond James set a $33.00 target price on LKQ and gave the stock a “buy” rating in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have given a buy rating to the stock. SAGE Therapeutics presently has a consensus rating of “Buy” and an average target price of $202.15.

The business has a 50 day moving average of $177.47. The stock has a market cap of $9.46 billion, a PE ratio of -23.47 and a beta of 2.55. The company has a current ratio of 20.06, a quick ratio of 20.06 and a debt-to-equity ratio of 0.03.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($3.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.17) by ($0.20). The company had revenue of $0.47 million during the quarter. During the same quarter in the prior year, the firm posted ($1.68) EPS. On average, sell-side analysts predict that SAGE Therapeutics Inc will post -13.19 earnings per share for the current fiscal year.

In related news, CEO Jeffrey M. Jonas sold 84,661 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $174.83, for a total transaction of $14,801,282.63. Following the transaction, the chief executive officer now owns 97,851 shares in the company, valued at approximately $17,107,290.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeffrey M. Jonas sold 94,264 shares of SAGE Therapeutics stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $174.75, for a total value of $16,472,634.00. Following the completion of the transaction, the chief executive officer now owns 116,023 shares in the company, valued at $20,275,019.25. The disclosure for this sale can be found here. Insiders have sold a total of 226,925 shares of company stock worth $39,438,777 in the last 90 days. 4.60% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in the business. FMR LLC grew its stake in shares of SAGE Therapeutics by 8.2% in the 1st quarter. FMR LLC now owns 7,608,239 shares of the biopharmaceutical company’s stock valued at $1,210,091,000 after purchasing an additional 575,163 shares during the last quarter. BlackRock Inc. grew its stake in shares of SAGE Therapeutics by 6.5% in the 1st quarter. BlackRock Inc. now owns 2,673,467 shares of the biopharmaceutical company’s stock valued at $425,216,000 after purchasing an additional 162,976 shares during the last quarter. Jennison Associates LLC grew its stake in shares of SAGE Therapeutics by 163.0% in the 1st quarter. Jennison Associates LLC now owns 2,355,614 shares of the biopharmaceutical company’s stock valued at $374,660,000 after purchasing an additional 1,459,950 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of SAGE Therapeutics by 440.6% in the 1st quarter. Janus Henderson Group PLC now owns 1,668,629 shares of the biopharmaceutical company’s stock valued at $265,395,000 after purchasing an additional 1,359,947 shares during the last quarter. Finally, OppenheimerFunds Inc. grew its stake in shares of SAGE Therapeutics by 0.3% in the 1st quarter. OppenheimerFunds Inc. now owns 1,443,145 shares of the biopharmaceutical company’s stock valued at $229,531,000 after purchasing an additional 4,721 shares during the last quarter.

About SAGE Therapeutics (NASDAQ:SAGE)

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Featured Story: Conference Calls and Individual Investors

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.